Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy Fleischmann

Showing results (181-190 of 190) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 190 results.
Arthritis & Rheumatology (Hoboken, N.J.)|March 14, 2024
Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-Enriched Rheumatoid Arthritis PatientsChristina Charles-Schoeman, Roy Fleischmann, Eduardo Mysler, et al.
Annals of the Rheumatic Diseases|April 16, 2026
Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH studyEduardo Mysler, Prodromos I Sidiropoulos, Andra Balanescu, et al.
Annals of the Rheumatic Diseases|August 14, 2020
Infections in baricitinib clinical trials for patients with active rheumatoid arthritisKevin L Winthrop, Masayoshi Harigai, Mark C Genovese, et al.
Arthritis Care & Research|June 28, 2012
Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activityJeffrey R Curtis, Annette H van der Helm-van Mil, Rachel Knevel, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 4, 2015
Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III StudyMark C Genovese, Roy Fleischmann, Alan J Kivitz, et al.
Arthritis and Rheumatism|January 26, 2013
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic studyDésirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann, et al.
Journal of Psoriasis and Psoriatic Arthritis|August 22, 2017
National Psoriasis Foundation Priorities for Patient-Centered Research: Proceedings from the 2016 ConferenceLadan Afifi, Lindsey Shankle, April W Armstrong, et al.
Arthritis and Rheumatism|September 5, 2002
Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging studyDaniel E Furst, Kenneth Saag, M Roy Fleischmann, et al.
Annals of the Rheumatic Diseases|March 28, 2013
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012Daniel E Furst, Edward Clark Keystone, Alexander K So, et al.
Annals of the Rheumatic Diseases|March 4, 2025
Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 updatePeter Nash, Andreas Kerschbaumer, Victoria Konzett, et al.
Pageof 19

Showing results (181-190 of 190) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 190 results.
Arthritis & Rheumatology (Hoboken, N.J.)|March 14, 2024
Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-Enriched Rheumatoid Arthritis PatientsChristina Charles-Schoeman, Roy Fleischmann, Eduardo Mysler, et al.
Annals of the Rheumatic Diseases|April 16, 2026
Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH studyEduardo Mysler, Prodromos I Sidiropoulos, Andra Balanescu, et al.
Annals of the Rheumatic Diseases|August 14, 2020
Infections in baricitinib clinical trials for patients with active rheumatoid arthritisKevin L Winthrop, Masayoshi Harigai, Mark C Genovese, et al.
Arthritis Care & Research|June 28, 2012
Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activityJeffrey R Curtis, Annette H van der Helm-van Mil, Rachel Knevel, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 4, 2015
Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III StudyMark C Genovese, Roy Fleischmann, Alan J Kivitz, et al.
Arthritis and Rheumatism|January 26, 2013
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic studyDésirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann, et al.
Journal of Psoriasis and Psoriatic Arthritis|August 22, 2017
National Psoriasis Foundation Priorities for Patient-Centered Research: Proceedings from the 2016 ConferenceLadan Afifi, Lindsey Shankle, April W Armstrong, et al.
Arthritis and Rheumatism|September 5, 2002
Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging studyDaniel E Furst, Kenneth Saag, M Roy Fleischmann, et al.
Annals of the Rheumatic Diseases|March 28, 2013
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012Daniel E Furst, Edward Clark Keystone, Alexander K So, et al.
Annals of the Rheumatic Diseases|March 4, 2025
Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 updatePeter Nash, Andreas Kerschbaumer, Victoria Konzett, et al.
Pageof 19